Sumatriptan-naproxen sodium in migraine: A review
Wilcha, Robyn-Jenia Afridi, Shazia K Barbanti, Piero Diener, Hans Christoph Jürgens, Tim Patrick Lanteri-Minet, Michel Lucas, Christian Mawet, Jerôme Moisset, Xavier Russo, Antonio
Wilcha, Robyn-Jenia
Afridi, Shazia K
Barbanti, Piero
Diener, Hans Christoph
Jürgens, Tim Patrick
Lanteri-Minet, Michel
Lucas, Christian
Mawet, Jerôme
Moisset, Xavier
Russo, Antonio
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2024-10-01
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Background: Varied responses to acute migraine medications have been observed, with over one-third (34.5%) of patients reporting insufficient headache relief. Sumatriptan-naproxen sodium, a single, fixed-dose combination tablet comprising sumatriptan 85 mg and naproxen sodium 500 mg, was developed with the rationale of targeting multiple putative mechanisms involved in the pathogenesis of migraine to optimise acute migraine care.
Methods: A narrative review of clinical trials investigating sumatriptan-naproxen sodium for both adults and adolescents was performed in March 2024.
Results: Across a total of 14 clinical trials in nine publications, sumatriptan-naproxen sodium offered greater efficacy for 2-h pain freedom (14/14) and sustained pain-free response up to 24 h (13/14) compared with monotherapy and/or placebo for both adult and adolescent study participants with an acceptable and well-tolerated adverse effect profile. Clinical trial data also demonstrates the effectiveness of sumatriptan-naproxen sodium in participants with allodynia, probable migraine, menstrual-related migraine and those with poor responses to acute, non-specific, migraine medication.
Conclusions: Multi-mechanistic therapeutic agents offer an opportunity to optimise acute medications by targeting multiple mediators involved in the pathogenesis of migraine. Sumatriptan-naproxen sodium resulted in greater initial and sustained pain freedom, compared with either sumatriptan, naproxen-sodium and/or placebo, for the treatment of single or multiple attacks of migraine across both adult and adolescent study populations.
Citation
Wilcha RJ, Afridi SK, Barbanti P, Diener HC, Jürgens TP, Lanteri-Minet M, Lucas C, Mawet J, Moisset X, Russo A, Sacco S, Sinclair AJ, Sumelahti ML, Tassorelli C, Goadsby PJ. Sumatriptan-naproxen sodium in migraine: A review. Eur J Neurol. 2024 Sep;31 Suppl 2(Suppl 2):e16434. doi: 10.1111/ene.16434.
Type
Article